Eli Lilly and Co (LLY)
733.32
+8.45
(+1.17%)
USD |
NYSE |
Apr 26, 16:00
733.50
+0.18
(+0.02%)
After-Hours: 20:00
Eli Lilly Research and Development Expense (Quarterly): 2.563B for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.563B |
| September 30, 2023 | 2.409B |
| June 30, 2023 | 2.356B |
| March 31, 2023 | 1.985B |
| December 31, 2022 | 1.996B |
| September 30, 2022 | 1.803B |
| June 30, 2022 | 1.782B |
| March 31, 2022 | 1.610B |
| December 31, 2021 | 1.898B |
| September 30, 2021 | 1.705B |
| June 30, 2021 | 1.655B |
| March 31, 2021 | 1.672B |
| December 31, 2020 | 1.838B |
| September 30, 2020 | 1.465B |
| June 30, 2020 | 1.390B |
| March 31, 2020 | 1.392B |
| December 31, 2019 | 1.581B |
| September 30, 2019 | 1.381B |
| June 30, 2019 | 1.402B |
| March 31, 2019 | 1.230B |
| December 31, 2018 | 1.392B |
| September 30, 2018 | 1.281B |
| June 30, 2018 | 1.271B |
| March 31, 2018 | 1.108B |
| December 31, 2017 | 1.226B |
| Date | Value |
|---|---|
| September 30, 2017 | 1.34B |
| June 30, 2017 | 1.272B |
| March 31, 2017 | 1.258B |
| December 31, 2016 | 1.517B |
| September 30, 2016 | 1.236B |
| June 30, 2016 | 1.336B |
| March 31, 2016 | 1.221B |
| December 31, 2015 | 1.444B |
| September 30, 2015 | 1.143B |
| June 30, 2015 | 1.170B |
| March 31, 2015 | 1.039B |
| December 31, 2014 | 1.186B |
| September 30, 2014 | 1.243B |
| June 30, 2014 | 1.195B |
| March 31, 2014 | 1.109B |
| December 31, 2013 | 1.475B |
| September 30, 2013 | 1.377B |
| June 30, 2013 | 1.330B |
| March 31, 2013 | 1.348B |
| December 31, 2012 | 1.463B |
| September 30, 2012 | 1.343B |
| June 30, 2012 | 1.321B |
| March 31, 2012 | 1.152B |
| December 31, 2011 | 1.355B |
| September 30, 2011 | 1.281B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.381B
Minimum
Sep 2019
2.563B
Maximum
Dec 2023
1.783B
Average
1.705B
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| Amgen Inc | 1.534B |
| Madrigal Pharmaceuticals Inc | 70.64M |
| Vertex Pharmaceuticals Inc | 824.60M |
| Viking Therapeutics Inc | 24.10M |
| Moderna Inc | 1.406B |